Spots Global Cancer Trial Database for Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

Official Title: Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma

Study ID: NCT04357873

Conditions

Squamous Cell Lung Cancer

Vulvar Cancer

Penile Cancer

Cervix Cancer

Head and Neck Squamous Cell Carcinoma

Anal Cancer

Interventions

pembrolizumab; vorinostat

Study Description

Brief Summary: Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)

Detailed Description: Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab in combination with vorinostat in adult patients with recurrent and/or metastatic squamous cell carcinoma of different locations. Antitumor activity of the combination will be evaluated using the objective response rate (ORR) during treatment (investigator assessment).